Streetbeat News

CALC

CalciMedica, Inc.

https://www.calcimedica.com

Industry

Biotechnology

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Open

2.36

Mkt cap

32M

Volume

15K

High

2.59

P/E Ratio

-2.12

52-wk high

6.26

Low

2.35

Div yield

N/A

52-wk low

2.05

CalciMedica Inc. (Nasdaq: CALC) will present at the 30th International AKI & CRRT Conference, showcasing their CRAC channel inhibition therapies for inflammatory and immunologic illnesses.

Portfolio Pulse from

February 19, 2025 | 12:15 pm

CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses.

Portfolio Pulse from

February 03, 2025 | 9:15 pm

CalciMedica Inc. has appointed Dr. Alan Glicklich to its Board of Directors. The company is focused on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses.

Portfolio Pulse from

January 14, 2025 | 12:15 pm

CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company, will participate in the Piper Sandler 36th Annual Healthcare Conference. The company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses.

Portfolio Pulse from

November 21, 2024 | 1:15 pm

CalciMedica Inc. (Nasdaq: CALC) announced that it will present findings from its Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis at two upcoming medical meetings. These presentations could increase visibility and interest in CalciMedica's research and potential treatments.

Portfolio Pulse from

November 20, 2024 | 9:15 pm

CalciMedica Inc. reported its Q3 2024 financial results, highlighting positive data from its CARPO Phase 2b trial for Auxora™ in acute pancreatitis. The company plans to start a Phase 3 program in 2025. Enrollment continues for trials in acute kidney injury and asparaginase-induced pancreatic toxicity, with data expected in 2025. Following a public offering, CalciMedica's cash position is expected to support operations until mid-2026.

Portfolio Pulse from

November 13, 2024 | 12:15 pm

CalciMedica, a clinical-stage biopharmaceutical company, has appointed Stephen Bardin as its new Chief Financial Officer, replacing Interim CFO Daniel Geffken. This leadership change comes as the company focuses on developing CRAC channel inhibition therapies.

Portfolio Pulse from

November 07, 2024 | 12:15 pm

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

CalciMedica's stock is trading lower following the announcement of a $10.2 million common stock offering.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:45 pm

The article highlights significant pre-market movements in healthcare stocks on Thursday. Notable gainers include Autonomix Medical, Tenon Medical, and Aerovate Therapeutics, while Matinas BioPharma and Equillium are among the biggest losers. Several companies reported Q3 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.